This clinical trial is for men and women who have a solid tumor cancer (not a blood cancer) that has worsened and has not responded to at least one prior cancer treatment. Participants’ tumor DNA must also have an error in one of the genes associated with the homologous recombination (HR) pathway including but not limited to BRCA1 or 2 (Breast Cancer 1 or 2).
   

This clinical trial is for men and women who have been diagnosed with colorectal cancer that has spread to their liver and are eligible for standard of care surgery to remove tumors in their liver.
   

The goal of this study is to better understand the biology underlying plasma cell disorders.

To accomplish this goal, we have created a database-biorepository which is being used by investigators at Weill Cornell Medicine and their collaborators. By studying the clinical course of patients with plasma cell disorders, and by performing basic laboratory studies using their tissue, we hope to improve patient care.

The purpose of this study is to better understand how well the medication REBYOTA is working to prevent recurrence of CDI (Clostridioides Difficile Infection) among adults following antibiotic treatment. The study also aims to understand patient-reported outcomes and health care utilization (e.g., doctors’ visits, and hospitalizations) after receiving REBYOTA. 

REBYOTA prevents recurrence of CDI among adults following antibiotic treatment and this drug is approved by the U.S. Food and Drug Administration (FDA).

This phase III trial compares the effect of modified fluorouracil, leucovorin calcium, oxaliplatin, and irinotecan (mFOLFIRINOX) to modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX) for the treatment of advanced, unresectable, or metastatic HER2 negative esophageal, gastroesophageal junction, and gastric adenocarcinoma.

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T cell therapy participating in a previous Celgene-sponsored or Celgene alliance partner-sponsored study.

This is a Phase 2 randomized, open-label, two-part, multicenter study with a safety run-in to evaluate efficacy and safety of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus standard of care (SOC) [FOLFIRI/FOLFOX and bevacizumab] as second-line treatment of advanced colorectal cancer patients.

In Parts A and B, approximately 150 evaluable adult advanced colorectal cancer patients with measurable disease who have radiographically progressed during or following 1 line of systemic treatment will be enrolled in the study.

This study is comparing the efficacy of the study drug RO7198457 versus “watchful waiting” in patients with circulating tumor DNA (ctDNA) positive, surgically resected Stage II/III rectal cancer, or Stage II (high risk)/Stage III colon cancer.

The purpose of this study is to test the efficacy of the combination of the study drugs tazemetostat with mosunetuzumab and see what effects it has on untreated follicular lymphoma. An additional purpose of this study is to understand what side effects people may have when they receive both drugs together.

This is a study of vobramitamab duocarmazine (MGC018) in combination with lorigerlimab designed to characterize safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics, and preliminary antitumor activity. Participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors including, but not limited to, metastatic castration resistant prostate cancer, melanoma, pancreatic cancer, hepatocellular carcinoma (HCC), ovarian cancer, and renal cell carcinoma (RCC) will be enrolled.